MOUNTAIN VIEW, Calif., June 21 /PRNewswire-FirstCall/ -- Pharsight Corporation , a leading provider of software and strategic services for optimizing clinical drug development, announced today that CTC Laboratory Systems Corporation of Tokyo, Japan, will distribute to the Japanese market Pharsight(R) Knowledgebase Server(TM), PKS Reporter(TM), PKS Validation Suite(TM), and Pharsight Trial Simulator(TM).
“The addition of CTC as a Pharsight distributor will enhance our ability to sell and serve the Japanese pharmaceutical and biotechnology markets,” said Shawn O’Connor, Pharsight president and CEO. “Our PKS product line represents a significant client investment in state-of-the-art PK PD data management to drive higher productivity, regulatory compliance, and increased value of kinetic and dynamic data. In addition to selling PKS and Trial Simulator in Japan, CTC’s IT capability will help Japanese PKS clients realize higher benefit from Pharsight products through enhanced local support and integration services.”
About Pharsight Knowledgebase Server (PKS)
The Pharsight Knowledgebase Server (PKS) provides protected, structured storage, access and change tracking for PK/PD data, analyses and related files. PKS is directly integrated with WinNonlin(R) Enterprise, Pharsight’s industry-leading PK/PD modeling and analysis tool, for state-of-the-art modeling, analyses, as well as direct access to any ODBC-capable data source. In addition, PKS includes a desktop client to interface with SAS, NONMEM(R), S-PLUS(R) and SigmaPlot(R), and add-ins to manage Microsoft(R) Word and Excel documents. PKS can save file formats of any type (e.g., ASCII, JPG, DOC), to capture content from a wide variety of visualization and analysis tools.
About PKS Reporter
PKS Reporter provides an automated system for the authoring, updating, and review/approval of standard or customized reports and documents. It is directly integrated with the Pharsight Knowledgebase Server (PKS) and accesses data and modeling results saved by WinNonlin Enterprise, Pharsight’s industry-leading PK/PD modeling and analysis tool, as well as results from other analysis tools and data sources. Users can browse the PKS database, loading objects and values drawn from various analysis scenarios into tags inserted into the document. Standardized templates can be defined and PKS Reporter will step through the templates, tag by tag, allowing the user to select and insert specific objects to match the format specified in the template.
About PKS Validation Suite
PKS Validation Suite streamlines on-site validation of the PKS product. The Validation Suite provides document templates, test data, and a collection of automated and manual test scripts. Leveraging the PKS Validation Suite as a starting point for validation efforts can save PKS users months of time for planning, testing, and reporting.
About Pharsight Trial Simulator
Pharsight Trial Simulator balances ease-of-use with powerful technology (patent-pending) for defining and testing interactive drug models, exploring and communicating study design attributes, and performing statistical and sensitivity analysis through graphical and statistical summaries. Trial Simulator models encapsulate existing scientific knowledge, to help communicate and test trial ideas, and plan relevant, effective trials for every phase of clinical testing. Pharsight Trial Simulator illuminates risks and previews the range of expected results before R&D dollars are committed to further development of a drug, and human subjects are exposed to experimental therapies.
About Pharsight Corporation
Pharsight Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products. The company’s goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products.
Pharsight’s approach enhances the fundamental element of drug development success: strong decision-making. By adopting the Pharsight approach, customers acquire a new decision-making process with the potential to systematically improve every level and phase of their business and scientific processes. Pharsight Corporation is headquartered in Mountain View, California. Information about Pharsight is available at http://www.pharsight.com.
About CTC Laboratory Systems Corporation
CTC Laboratory Systems Corporation, headquartered in Tokyo, is one of five subsidiaries of Itochu Techno Sciences Corporation, a $2.1 billion subsidiary of Japanese trading company Itochu. The parent company has operations in 80 countries. CTC focuses on the development, sale, and support of application systems for the chemical and pharmaceutical industries. CTC’s major lines of business include resale of hardware and software, local support services, IT solutions, and consulting. CTC’s clientele includes major global pharmaceutical Japanese companies such as Chugai, Astellas, and Takeda, together with local operations of US and European major pharma. In addition to Pharsight, CTC distributes and supports a full portfolio of solutions for leading life sciences vendors including Oracle Clinical (clinical data management), Documentum (content management), and Applied Biosystems (laboratory information management). Additional information is available at: http://rose.ctc-g.co.jp/rose/en/#01.
Forward Looking Statements
This press release contains forward-looking statements that involve risks and uncertainties, including statements regarding anticipated sales performance and the performance of Pharsight’s products and the expected benefits to customers from the use of such products. Actual results may differ materially from Pharsight’s expectations due to a variety of factors, including general market and business conditions, uncertainties involved in pharmaceutical drug development, changes in the demand for Pharsight’s services, the failure to develop new services or to keep pace with technological changes, the failure of Pharsight’s products to obtain anticipated levels of customer acceptance or to meet customers’ expectations, and changes in government regulation of the pharmaceutical industry. Further information on potential factors that could affect actual results is included in Pharsight’s Quarterly Report on Form 10-Q, as filed with the Securities and Exchange Commission on February 13, 2006. All forward-looking statements are based on information available to Pharsight as of the date hereof, and Pharsight assumes no obligation to update such statements, whether as a result of new developments or otherwise.
Registered Trademarks and Trademarks
Pharsight(R), Pharsight(R) Knowledgebase Server(TM), PKS Reporter(TM), PKS Validation Suite(TM), WinNonlin(R) Enterprise, and Pharsight Trial Simulator(TM) are trademarks or registered trademarks of Pharsight Corporation. SAS, NONMEM(R), S-PLUS(R), SigmaPlot(R), Microsoft(R) Word and Microsoft(R) Excel are trademarks or registered trademarks of their respective holders.
Pharsight Corporation
CONTACT: investors, Douglas Sherk, or Jennifer Beugelmans, both of EVCGroup, +1-415-896-6820, for Pharsight, or media, Steve DiMattia of EVCGroup, +1-646-277-8706, for Pharsight
Web site: http://www.pharsight.com//
